Fresenius Kabi has launched its subcutaneous formulation of Tyenne® (tocilizumab-aazg), biosimilar to Roche’s Actemra® (tocilizumab), in the United States. This new formulation provides patients with primary immunodeficiency diseases a convenient alternative to intravenous administration.
Both subcutaneous and intravenous forms of Tyenne were FDA approved on 5 March 2024. Fresenius launched the IV formulation of Tyenne in the US in April 2024. Fresenius Kabi launched Tyenne in Europe as the first to market biosimilar in November 2023 in both IV and SC formulations.